(Q21245712)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

author

José María López-Picazo

4

Jose M Lopez-Picazo

Jose M

Lopez-Picazo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

7

Ruben Pio

Ruben

Pio

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Yi-Fan Hsu

1

Yi-Fan

Hsu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Daniel Ajona

2

Daniel

Ajona

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Leticia Corrales

3

Leticia

Corrales

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Alfonso Gurpide

5

Alfonso

Gurpide

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Luis M Montuenga

6

Luis M

Montuenga

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

English

0 references

publication date

7 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

1

0 references

page(s)

139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

New molecularly targeted therapies for lung cancer

4 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

19 March 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

EGFR antagonists in cancer treatment

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Update in lung cancer 2008

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Mechanisms of killing by anti-CD20 monoclonal antibodies.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Complement mediated cell death is associated with DNA fragmentation

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2893457

Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor

29 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20529262

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20529262

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1476-4598-9-139

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

4 February 2020

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1476-4598-9-139

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20529262%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

PubMed publication ID

20529262

2 references